1. 要旨
2. 分類学と市場定義を含む業界紹介
3. 市場動向と成功要因（マクロ経済要因、市場ダイナミクス、最近の業界動向など
4. 歴史分析と将来予測を含む世界市場の需要分析2019年～2023年および予測2024年～2034年
5. 世界市場の分析 2019～2023年および2024～2034年予測
5.1. 薬剤クラス
5.2. 適応症
5.3. 投与経路
5.4. 流通経路
6. 薬剤クラス別の世界市場分析2019〜2023年および予測2024〜2034年
6.1. トロンボポエチン受容体作動薬（TRAs）
6.2. プロテアソーム阻害薬
6.3. 赤血球造血刺激因子製剤（ESAs）
6.4. 顆粒球コロニー刺激因子（G-CSFs）
6.5. その他のペプチド治療薬
7. 世界市場分析2019～2023年および予測2024～2034年：適応症別
7.1. 血小板減少症
7.2. 多発性骨髄腫
7.3. 貧血
7.4. 好中球減少
7.5. 血友病
7.6. 鎌状赤血球貧血
7.7. 白血病とリンパ腫
7.8. その他
8. 世界市場分析2019～2023年および予測2024～2034年：投与経路別
8.1. 注射剤
8.2. 経口剤
9. 世界市場分析2019～2023年および予測2024～2034年：流通チャネル別
9.1. 病院薬局
9.2. 小売薬局
9.3. 専門薬局
9.4. オンライン薬局
10. 世界市場分析2019～2023年および予測2024～2034年、地域別
10.1. 北米
10.2. 中南アメリカ
10.3. ヨーロッパ
10.4. アジア太平洋
10.5. 中東・アフリカ
11. 北米の主要セグメント・国別売上高分析 2019～2023年および予測 2024～2034年
12. 中南アメリカ売上高分析 2019～2023年および2024～2034年予測：主要セグメント・国別
13. ヨーロッパの売上高分析 2019～2023年および2024～2034年予測：主要セグメント・国別
14. アジア太平洋地域の売上高分析 2019～2023年および2024～2034年予測：主要セグメント・国別
15. 中東・アフリカ地域 売上高分析 2019～2023年および2024～2034年予測：主要セグメント・国別
16. 2024～2034年までの売上高予測（30ヵ国：薬効分類、適応症、投与経路、流通チャネル別
17. 市場構造分析、主要企業別シェア分析、競合ダッシュボードを含む競合展望
18. 企業プロフィール
18.1. Amgen, Inc.
18.2. Johnson & Johnson （Janssen Pharmaceuticals）
18.3. Roche （Chugai Pharmaceutical）
18.4. Novartis AG
18.5. Sanofi S.A.
18.6. Pfizer, Inc.
18.7. Takeda Pharmaceutical Company
18.8. Eli Lilly and Company
18.9. Biogen, Inc.
18.10. GlaxoSmithKline （GSK）
18.11. Bristol Myers Squibb Company
18.12. AbbVie Inc.
18.13. Merck & Co., Inc.
18.14. AstraZeneca
18.15. Alexion Pharmaceuticals （AstraZeneca subsidiary）
Peptide Based Hematological Disorders Therapeutics Market - Scope of ReportA recent study by Fact.MR on the peptide based hematological disorders therapeutics market offers a 10-year forecast for 2024 to 2034. The study analyzes crucial trends that are currently determining the growth of the market. This report explicates on vital dynamics, such as the drivers, restraints, and opportunities for key market players along with key stakeholders as well as emerging players associated with offering peptide based hematological disorders therapeutics.
The study also provides the dynamics responsible for influencing the future status of the peptide based hematological disorders therapeutics market over the forecast period. A detailed assessment of value chain analysis, business execution, and supply chain analysis across regional markets has been covered in the report.
A list of prominent companies operating in the peptide based hematological disorders therapeutics market, along with their product portfolios, key strategies and SWOT analysis, enhances the reliability of this comprehensive research study.
Report Summary
The study offers comprehensive analysis on diverse features, including production capacities, demand, product developments, revenue generation, and sales of peptide based hematological disorders therapeutics across the globe.
A comprehensive estimate on the market has been provided through an optimistic as well as a conservative scenario, taking into account the sales of peptide based hematological disorders therapeutics during the forecast period. Price point comparison by region with global average price is also considered in the study.
Analysis on Market Size Evaluation
The market has been analyzed for each segment in terms of value (US$ Mn).
Estimates at global and regional levels for peptide based hematological disorders therapeutics are available in terms of “US$ Mn” for value. A Y-o-Y growth contrast on prominent market segments, along with market attractiveness evaluation, has been incorporated in the report. Furthermore, absolute dollar opportunity analysis of all the segments adds prominence to the report.
Absolute dollar opportunity plays a crucial role in assessing the level of opportunity that a manufacturer/distributor can look to achieve, along with identifying potential resources, considering the sales and distribution perspective in the global peptide based hematological disorders therapeutics market.
Inspected Assessment on Regional Segments
Key sections have been elaborated in the report, which have helped deliver projections on regional markets. These chapters include regional macros (political, economic, and business environment outlook), which are expected to have a momentous influence on the growth of the peptide based hematological disorders therapeutics market during the forecast period.
Country-specific valuation on demand for peptide based hematological disorders therapeutics has been offered for each region, along with market scope estimates and forecasts, price index, and impact analysis of the dynamics of prominence in regions and countries. For all regional markets, Y-o-Y growth estimates have also been incorporated in the report.
Detailed breakup in terms of value & volume for emerging countries has also been included in the report.
In-depth Analysis on Competition
The report sheds light on leading manufacturers of peptide based hematological disorders therapeutics, along with their detailed profiles. Essential and up-to-date data related to market performers who are principally engaged in offering peptide based hematological disorders therapeutics has been brought with the help of a detailed dashboard view. Market share analysis and comparison of prominent players provided in the report permits report readers to take preemptive steps in advancing their businesses.
Company profiles have been included in the report, which include essentials such as product portfolios and key strategies, along with all-inclusive SWOT analysis on each player. Company presence is mapped and presented through a matrix for all the prominent players, thus providing readers with actionable insights, which helps in thoughtfully presenting the market status, and predicting the competition level in the peptide based hematological disorders therapeutics domain.
1. Executive Summary
2. Industry Introduction, including Taxonomy and Market Definition
3. Market Trends and Success Factors, including Macro-economic Factors, Market Dynamics, and Recent Industry Developments
4. Global Market Demand Analysis 2019 to 2023 and Forecast 2024 to 2034, including Historical Analysis and Future Projections
5. Global Market Analysis 2019 to 2023 and Forecast 2024 to 2034
5.1. Drug Class
5.2. Indication
5.3. Route of Administration
5.4. Distribution Channel
6. Global Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Drug Class
6.1. Thrombopoietin Receptor Agonists (TRAs)
6.2. Proteasome Inhibitors
6.3. Erythropoiesis-Stimulating Agents (ESAs)
6.4. Granulocyte Colony-Stimulating Factors (G-CSFs)
6.5. Other Peptide Therapeutics
7. Global Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Indication
7.1. Thrombocytopenia
7.2. Multiple Myeloma
7.3. Anemia
7.4. Neutropenia
7.5. Hemophilia
7.6. Sickle Cell Anemia
7.7. Leukemia and Lymphoma
7.8. Others
8. Global Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Route of Administration
8.1. Injectable
8.2. Oral
9. Global Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Distribution Channel
9.1. Hospital Pharmacies
9.2. Retail Pharmacies
9.3. Specialty Pharmacies
9.4. Online Pharmacies
10. Global Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Region
10.1. North America
10.2. Latin America
10.3. Europe
10.4. Asia Pacific
10.5. Middle East & Africa
11. North America Sales Analysis 2019 to 2023 and Forecast 2024 to 2034, by Key Segments and Countries
12. Latin America Sales Analysis 2019 to 2023 and Forecast 2024 to 2034, by Key Segments and Countries
13. Europe Sales Analysis 2019 to 2023 and Forecast 2024 to 2034, by Key Segments and Countries
14. Asia Pacific Sales Analysis 2019 to 2023 and Forecast 2024 to 2034, by Key Segments and Countries
15. Middle East & Africa Sales Analysis 2019 to 2023 and Forecast 2024 to 2034, by Key Segments and Countries
16. Sales Forecast 2024 to 2034 by Drug Class, Indication, Route of Administration, and Distribution Channel for 30 Countries
17. Competition Outlook, including Market Structure Analysis, Company Share Analysis by Key Players, and Competition Dashboard
18. Company Profile
18.1. Amgen, Inc.
18.2. Johnson & Johnson (Janssen Pharmaceuticals)
18.3. Roche (Chugai Pharmaceutical)
18.4. Novartis AG
18.5. Sanofi S.A.
18.6. Pfizer, Inc.
18.7. Takeda Pharmaceutical Company
18.8. Eli Lilly and Company
18.9. Biogen, Inc.
18.10. GlaxoSmithKline (GSK)
18.11. Bristol Myers Squibb Company
18.12. AbbVie Inc.
18.13. Merck & Co., Inc.
18.14. AstraZeneca
18.15. Alexion Pharmaceuticals (AstraZeneca subsidiary)
❖ 免責事項 ❖
http://www.globalresearch.jp/disclaimer
